Terminated

Studies may be terminated early for various reasons, including operational challenges, safety concerns, or new findings that indicate they should not or do not need to proceed.

Showing results.

Terminated

Prevention & Testing

Ontario Region

Prairies Region

CTN 332: vPrEP
Virtual PrEP: Rendering PrEP delivery more efficient using an mHealth intervention and TAF/FTC
Terminated

Treatment & Management

BC & Yukon Region

CTNPT 014: Kaletra®/Celsentri® combination therapy for HIV in the setting of HCV
An observational study of Kaletra®/Celsentri® combination therapy
Terminated

Treatment & Management

CTN 227: Hepatitis C therapeutic vaccine
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
Terminated

Treatment & Management

CTNPT 019: Improving outcomes with Metformin
Can metformin prevent the progression of liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance?
Terminated

Cure & Immunotherapies

CTNPT 020: Therapeutic HIV vaccine with early HAART treatment initiation
A pilot randomized, open label study to evaluate the effect of a therapeutic HIV vaccine consisting of PENNVAX®-GP (gag, pol, env) and INO-9012 DNA vaccine delivered via electroporation on reducing HIV viral reservoirs in infected individuals, who initiated therapy during the acute/early phase of infection
Terminated

Cure & Immunotherapies

CTNPT 022A: PROOV IT I
Probiotic Visbiome for Inflammation and Translocation in HIV (PROOV IT I)

Careers

Interested in joining our team? Here are the current career opportunities with the CTN+ and our collaborators. For Fellowship opportunities, please visit our Postdoctoral Fellowship program page.v

Learn More

Terminated

CTN 332: vPrEP

CTNPT 014: Kaletra®/Celsentri® combination therapy for HIV in the setting of HCV

CTN 227: Hepatitis C therapeutic vaccine

CTNPT 019: Improving outcomes with Metformin

CTNPT 020: Therapeutic HIV vaccine with early HAART treatment initiation

CTNPT 022A: PROOV IT I

Careers